Igm Biosciences, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
8-K: IGM Biosciences to be Acquired by Concentra Biosciences in Cash and Contingent Value Right Deal
IGM Biosciences, Inc. has entered into a definitive merger agreement to be acquired by Concentra Biosciences, LLC for $1.247 per share in cash plus a contingent value right, with the transaction expected to close in August 2025.
IGM Biosciences, Inc. has received a notice from Nasdaq indicating non-compliance with the minimum Market Value of Listed Securities requirement, initiating a 180-day period to regain compliance.
IGM Biosciences, Inc. has announced the early termination of its headquarters lease in Mountain View, California, effective May 31, 2025, in exchange for a $14.2 million termination payment and conveyance of certain assets.
IGM Biosciences announced the termination of its collaboration agreement with Sanofi, resulting in a significant workforce reduction and facility closures as the company explores strategic alternatives.
IGM Biosciences amends its previous 8-K filing to provide estimated restructuring charges between $0.7 million and $2.0 million following the halt of imvotamab and IGM-2644 development for autoimmune diseases.
8-K: IGM Biosciences Halts Autoimmunity Programs, Implements Restructuring with 73% Workforce Reduction
IGM Biosciences announces a strategic shift, discontinuing development of imvotamab and IGM-2644 for autoimmune diseases and reducing its workforce by 73% to preserve cash.
IGM Biosciences reported its Q3 2024 financial results, highlighted by a strategic shift to focus on autoimmunity and progress in clinical trials for its lead drug candidates.
IGM Biosciences estimates restructuring charges between $11.7 million and $14.4 million due to a strategic pivot and pipeline transformation.
IGM Biosciences is shifting its focus to autoimmune disease treatments, discontinuing oncology programs, and has appointed Mary Beth Harler as CEO, extending its cash runway into 2027.
8-K: IGM Biosciences Announces Positive Clinical Trial Updates and Second Quarter 2024 Financial Results
IGM Biosciences reports completion of enrollment in a key colorectal cancer trial and advancements in autoimmune disease trials, alongside its Q2 2024 financial results.
IGM Biosciences has revised its 2024 collaboration revenue guidance to approximately $2 million, with $1 million expected in Q2, due to an accounting analysis following a refocus of its collaboration with Sanofi.
IGM Biosciences successfully held its 2024 annual meeting, electing directors, ratifying the accounting firm, and approving amendments to the certificate of incorporation and a stock option exchange program.
IGM Biosciences announced positive enrollment updates for its aplitabart and imvotamab clinical trials, along with its first quarter 2024 financial results.
IGM Biosciences and Sanofi have revised their collaboration agreement to focus exclusively on immunology and inflammation targets, with IGM retaining rights to oncology targets.
IGM Biosciences announced its fourth quarter and full year 2023 financial results, highlighting progress in clinical trials for its lead product candidates and providing a corporate update.